Downstream processing market will grow to record $40bn by 2026
The global downstream processing market is predicted to witness record-breaking growth due to a surge in the adoption of biotech processes.
List view / Grid view
The global downstream processing market is predicted to witness record-breaking growth due to a surge in the adoption of biotech processes.
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
The FDA has announced Orphan Drug Designation for Imfinzi (durvalumab) to treat small cell lung cancer in combination with other therapies.
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
The FDA and EMA have agreed to rely on each other’s assessment of pharmaceutical manufacturing sites to reduce duplicative work.
A federal judge in the US has said that the Trump administration cannot require pharmaceutical companies to include drug prices in advertisements as it is beyond their authority.
Pharmaceutical packaging in China has increased at a rate of 10 percent in recent years and is predicted to continue high growth.
Seven medications have been suggested for removal from prescriptions by the NHS after a public consultation.
The rise of diseases such as inflammatory bowel syndrome is projected to drive the global gastrointestinal drugs market in the upcoming years.
The EU has issued two guidance documents intended to advise the pharmaceutical industry and patients during medicinal shortages.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
New regulations and legislations are being formed in the US to combat healthcare costs, including drug prices.
The DHSC has announced their plans for pharmaceutical transportation in the case of a no-deal Brexit.
A pharmaceutical company will appeal a decision by NICE to not recommend osimertinib for use within NHS England.